Within the 260 patients, only those who harbored latent metastatic cancer cells but had not developed BCR yet could benefit from adjuvant therapies, while the rest “majority” of them were more likely to only suffer from side effects of over treatments. The gene discussed is BCR; the disease is metastatic malignant neoplasm.